CEL-SCI Corporation (CVM) compared with its closest peers (TIL, MGX, ALGS, ELUT, QNCX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Instil Bio, Inc. (TIL) | $51.81M | -1.0 |
| Metagenomi, Inc. Common Stock (MGX) | $46.09M | -0.7 |
| Aligos Therapeutics, Inc. (ALGS) | $41.03M | -3.8 |
| Elutia Inc. (ELUT) | $37.98M | 0.8 |
| Quince Therapeutics, Inc. (QNCX) | $33.82M | -2.0 |
| Jasper Therapeutics, Inc. (JSPR) | $26.29M | -0.5 |
| Dyadic International, Inc. (DYAI) | $25.49M | — |
| Intensity Therapeutics, Inc. (INTS) | $15.88M | -0.0 |
| Passage Bio, Inc. (PASG) | $14.09M | -0.8 |
| Senti Biosciences, Inc. (SNTI) | $11.84M | -0.4 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
CVM overview · CVM earnings · CVM financials · CVM KPIs · CVM investor relations · CVM ownership · CVM filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.